The short version of growth hormone fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-21. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C221H366N72O67S | Reflects a 44-residue peptide with one N-terminal modification |
| Approximate molecular weight | 5136 Da | Sequence length and single acyl group determine the mass |
| Appearance | White to off-white lyophilized powder | Typical form of a purified synthetic peptide |
| Solubility class | Soluble in water and aqueous buffer | Peptide backbone favors aqueous dissolution |
| Common synonyms | GHRH(1-44) analogue; Egrifta | Descriptive name and approved brand name |
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
Since the prohibition of the 1960s and 1970s, clinical research into psychedelics started to resume by the 1990s, for instance the studies of DMT by Rick Strassman, and they have once again started to be developed as pharmaceutical drugs for potential medical use. A so-called "psychedelic renaissance", in which interest in psychedelics has resurged, began in the late 2010s and early 2020s. Michael Pollan's 2018 book How to Change Your Mind, which was also adapted into a Netflix series in 2022, was especially impactful in terms of increasing mainstream awareness and interest in psychedelics. More than 100 clinical trials of four major psychedelics, including psilocybin, LSD, ayahuasca, and MDMA, were identified as being underway in 2024.
=== Copper toxicity === The classic copper-catalyzed azide-alkyne cycloaddition has been an extremely fast and effective click reaction for bioconjugation, but it is not suitable for use in live cells due to the toxicity of Cu(I) ions. Toxicity is due to oxidative damage from reactive oxygen species formed by the copper catalysts. Copper complexes have also been found to induce changes in cellular metabolism and are taken up by cells. There has been some development of ligands to prevent biomolecule damage and facilitate removal in in vitro applications. However, it has been found that different ligand environments of complexes can still affect metabolism and uptake, introducing an unwelcome perturbation in cellular function.
=== EC 1.14.20 With 2-oxoglutarate as one donor, and the other dehydrogenated === EC 1.14.20.1: deacetoxycephalosporin-C synthase EC 1.14.20.2: Now EC 1.14.11.59, 2,4-dihydroxy-1,4-benzoxazin-3-one-glucoside dioxygenase EC 1.14.20.3: (5R)-carbapenem-3-carboxylate synthase EC 1.14.20.4: anthocyanidin synthase EC 1.14.20.5: flavone synthase I EC 1.14.20.6: flavonol synthase EC 1.14.20.7: 2-oxoglutarate/L-arginine monooxygenase/decarboxylase (succinate-forming) EC 1.14.20.8: (–)-deoxypodophyllotoxin synthase EC 1.14.20.9: L-tyrosine isonitrile desaturase EC 1.14.20.10: L-tyrosine isonitrile desaturase/decarboxylase EC 1.14.20.11: 3-[(Z)-2-isocyanoethenyl]-1H-indole synthase EC 1.14.20.12: 3-[(E)-2-isocyanoethenyl]-1H-indole synthase EC 1.14.20.13: 6β-hydroxyhyoscyamine epoxidase EC 1.14.20.14: hapalindole-type alkaloid chlorinase EC 1.14.20.15: L-threonyl-[L-threonyl-carrier protein] 4-chlorinase
Sources: en.wikipedia.org
Dr. Samuel (Sam) Lofquist, DMD is an American biological dentist. He is the founder of Biological Dentistry of Southern California in San Juan Capistrano, California, a clinic specializing in surgically based biological dentistry, zirconia (ceramic) implants, advanced bone grafting techniques, airway dentistry, and SMART amalgam removal. Dr. Lofquist completed the Tufts University Maxi Residency in Biological Dentistry, Biological Surgery, Implantology, focused on Guided Open Wound Healing. Prior to his dental career, he was a professional hockey player for parts of 12 seasons in North America, Sweden, Finland, Russia, Switzerland, and China. Dr. Lofquist started down his dental and biological dentistry journey after sustaining an oral injury to his front four teeth while playing in the Spengler Cup in Davos, Switzerland, and observing his health take a step backwards. Upon receiving biological dental treatment for his oral conditions, his health was able to recover. He then decided to pursue a career in biological dentistry.
Indium is produced exclusively as a by-product during the processing of the ores of other metals. Its main source materials are sulfidic zinc ores, where it is mostly hosted by sphalerite. Minor amounts are also extracted from sulfidic copper ores. During the roast-leach-electrowinning process of zinc smelting, indium accumulates in the iron-rich residues. From these, it can be extracted in different ways. It may also be recovered directly from the process solutions. Further purification is done by electrolysis. The exact process varies with the mode of operation of the smelter. Its by-product status means that indium production is constrained by the amount of sulfidic zinc (and copper) ores extracted each year. Therefore, its availability needs to be discussed in terms of supply potential. The supply potential of a by-product is defined as that amount which is economically extractable from its host materials per year under current market conditions (i.e. technology and price). Reserves and resources are not relevant for by-products, since they cannot be extracted independently from the main-products. Recent estimates put the supply potential of indium at a minimum of 1,300 t/yr from sulfidic zinc ores and 20 t/yr from sulfidic copper ores. These figures are significantly greater than current production (655 t in 2016). Thus, major future increases in the by-product production of indium will be possible without significant increases in production costs or price. The average indium price in 2016 was US$240/kg, down from US$705/kg in 2014.
== Action mechanism, pharmacokinetics == Like other local anesthetics belonging in the amide group trimecaine decreases the cell membrane permeability, causes depolarization and shortens the action potential. Anesthetic effect starts within 15 minutes and remains 60–90 minutes. Its biological half-life is ca. 90 minutes. 10% of trimecaine is excreted unchanged (90% as its metabolites). It passes through the hematoencephalic and placental barriers.
Sources: en.wikipedia.org
In the prosecution's filing ahead of sentencing, federal prosecutors made allegations of sexual misconduct against Hastert (the first time they had done so publicly), saying that he had molested at least four boys as young as 14 (including Steve Reinboldt and others) while he worked as a high school wrestling coach decades earlier. In a 26-page filing, prosecutors detailed "specific, graphic iancidents" of sexual acts. Prosecutors asked for a six-month sentence, as called for under federal sentencing guidelines. Prosecutors also requested the court to order Hastert to undergo a sex offender evaluation and comply with any recommended treatment. While Hastert's health problems had the possibility to help him avoid prison, prosecutors noted in their court filing that he could receive medical treatment while incarcerated, if necessary. Sixty letters asking for leniency for Hastert were submitted to the court ahead of sentencing, but 19 of these letters were withdrawn after Judge Durkin said that he would not consider any letters that were not made public. Of the 41 letters that were made public, several were from current or former members of Congress: Tom DeLay, John T. Doolittle, David Dreier, Thomas W. Ewing, and Porter Goss (who is also a former CIA director). The Chicago Tribune noted that DeLay and Doolittle "have had legal troubles of their own" stemming from the Abramoff scandal, although DeLay's conviction in that scandal was later overturned and Doolittle was never charged.
This retrogaming-themed special issue applied the format of the standard edition of Edge to classic video games. This was the most fully formed of the Edge specials, being an edition that only featured new material. "Retro: 'The making of...' special" (2002)
==== United States investigations ==== GlaxoSmithKline was being investigated by the FDA and the US Congress regarding Avandia. Senators Democrat Max Baucus and Republican Charles Grassley filed a report urging GSK to withdraw Avandia in 2008 due to the side effects. The report noted the drug caused 500 avoidable heart attacks a month, and Glaxo officials sought to intimidate doctors who criticized the drug. It also said GSK continued to sell and promote the drug despite knowing the increased risk of heart attacks and stroke. The Senate Finance Committee, in a panel investigation, revealed emails from GSK company officials that suggest the company downplayed scientific findings about safety risks dating back to 2000. It was also alleged by the committee that the company initiated a "ghostwriting campaign", whereby GSK sought outside companies to write positive articles about Avandia to submit to medical journals. GSK defended itself by presenting data that its own tests found Avandia to be safe, although an FDA staff report showed the conclusions were flawed. On July 14, 2010, after two days of extensive deliberations, the FDA panel investigating Avandia came to a mixed vote. Twelve members of the panel voted to take the drug off the market, 17 recommended to leave it on but with a more revised warning label, and three voted to keep it on the market with the current warning label.
Sources: en.wikipedia.org
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.
It binds the growth hormone-releasing hormone receptor on anterior pituitary cells. Activation of that receptor promotes synthesis and release of growth hormone. The effect propagates through the growth hormone and insulin-like growth factor 1 axis.
Native GHRH is cleared quickly by peptidases, which limits how long it can stimulate its receptor. The added group hinders one of the primary cleavage enzymes. The practical consequence is a longer period of receptor activity per dose.
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.